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Cardiovascular Magnetic Resonance assessment of 
1st generation CoreValve and 2nd generation Lotus valves 
ABSTRACT  
Objectives: We sought to compare using serial CMR, the quantity of AR and 
associated valve haemodynamics, following the first-generation CoreValve (Medtronic, 
Minneapolis, Minnesota) and the second-generation Lotus valve (Boston Scientific, 
Natick Massachusetts). 
Background: Aortic regurgitation (AR) following Transcatheter Aortic Valve 
Replacement (TAVR) confers a worse prognosis and can be accurately quantified using 
cardiovascular magnetic resonance (CMR). Second generation valves have been 
specifically designed to reduce paravalvular AR and improve clinical outcomes.  
Methods:  Fifty-one patients (79.0±7.7 years, 57% male) were recruited and imaged at 
three time points: immediately pre- and post-TAVR, and at 6 months. 
Results: CMR-derived AR fraction immediately post-TAVR was greater in the 
CoreValve compared to Lotus group (11.7±8.4 vs. 4.3±3.4%, p=0.001), as was the 
frequency oIPRGHUDWH$5YV. 0/27, p<0.001). However, at 6 months AR 
fraction had improved significantly in the CoreValve group such that the two valve 
designs were comparable (6.4±5.0 vs. 5.6±5.3%, p=0.623), with no patient in either 
JURXS KDYLQJ PRGHUDWH $5  The residual peak pressure gradient immediately 
following TAVR was significantly lower with CoreValve compared to Lotus (14.1±5.6 vs. 
25.4±11.6mmHg, p=0.001), but again by 6 months the two valve designs were 
comparable (16.5±9.4 vs. 19.7±10.5mmHg, p=0.332). There was no difference in the 
degree of LV reverse remodelling between the two valves at 6 months. 
Conclusion: Immediately post-TAVR, there was significantly less AR but a higher 
residual peak pressure gradient with the Lotus valve compared to CoreValve. However, 
at 6 months both devices had comparable valve haemodynamics and LV reverse 
2 
 
remodelling.  
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Abbreviations list 
AR:   aortic regurgitation 
AS:   aortic stenosis 
CMR:   cardiovascular magnetic resonance 
IQR:   interquartile range 
LV:   left ventricle 
LVEDP:  left ventricular end diastolic pressure 
LVEF   left ventricular ejection fraction 
MDCT:  multi detector computed tomography  
TAVR:  transcatheter aortic valve replacement 
VARC:  valve academic research consortium 
VENC:  velocity encoded gradient echo imaging 
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INTRODUCTION 
Transcatheter Aortic Valve Replacement (TAVR) device design has evolved in an 
attempt to improve both device success rates and clinical outcomes 1. However, aortic 
regurgitation (AR) is seen in up to 80% of patients following TAVR, affecting both the 
balloon-expandable and the self-expanding designs 2. This typically reflects incomplete 
circumferential apposition between the circular prosthesis and the oval-shaped aortic 
annulus 3 and is often compounded by extensive calcification, under-expansion of the 
TAVR prosthesis or malposition 4. Clinical trials and registry data have consistently 
shown that moderate or more paravalvular AR following TAVR is associated with 
reduced survival at short- and long-term term follow-up with all valve types 5-7. 
Cardiovascular magnetic resonance (CMR) is the reference modality for assessing LV 
mass, volumes and function. In addition, CMR permits full volumetric quantitation of AR 
that is highly accurate and reproducible 8, 9, independent of the number or eccentricity of 
regurgitant jets 10, and unlike echocardiography, is not limited by TAVR prosthesis or 
calcification artefact 3. CMR has lower intra-observer and inter-observer variability than 
echocardiography 11, 12 and thus is more suited to serial measurements. Compared with 
CMR, echocardiography underestimates AR following TAVR 8, 13, 14 and thus CMR 
offers a potentially superior prognostic assessment of the post-TAVR patient 14. 
Little is known about how AR evolves over time, especially with different valve designs, 
and how this might impact on LV reverse remodelling. Previous studies have indicated 
a reduction in AR over time with both the CoreValve and Edwards Sapien valve, but 
these data have been hampered by the limitations of transthoracic echocardiography in 
the assessment of paravalvular AR. The Boston Scientific Lotus valve has a unique 
adaptive seal specifically designed to minimise post-TAVR aortic regurgitation (AR) (8), 
that has proven to be both safe and effective in the REPRISE I 15 and REPRISE II 
studies 16. 
4 
 
The aim of this study was to accurately quantify, using serial CMR, the degree of AR 
over time following TAVR using the first generation self-expanding Medtronic CoreValve 
17-21
, and the second generation Boston Scientific Lotus valve, and to determine 
whether differences in aortic valve regurgitation and haemodynamics impact LV reverse 
remodelling.  
 
METHODS 
Study population 
This non-randomised study prospectively recruited 59 patients with severe tri-leaflet 
degenerative AS who were referred for TAVR at the Leeds Teaching Hospitals NHS 
Trust, UK, between March 2013 and May 2015. Severe AS was classified by 
echocardiography DVDQDRUWLFYDOYHDUHDRIcm2 or peak velocity >4m/s. Decision 
for TAVR in all cases was taken by a multidisciplinary heart team in accordance with 
international guidance 22. In the initial part of the study period only the CoreValve device 
was available. Subsequently, device selection was made by the TAVI Heart Team 
according to individual specific patient anatomy and clinical implantation indications. 
Exclusion criteria included any contraindication to CMR as well as patients with a 
known bicuspid aortic valve, aortopathy or previous aortic or mitral prostheses. The 
study was approved by the national research ethics committee, complied with the 
Declaration of Helsinki and all patients provided written informed consent. 
Transcatheter Aortic Valve Replacement 
TAVR was performed using either a first generation CoreValve system (Medtronic, 
Minneapolis, Minnesota, USA) or the /RWXV $RUWLF 9DOYH V\VWHP %RVWRQ 6FLHQWLILF
Corporation, Natick, MA, USA) employing standard techniques as previously described 
for both vendors 23, 24. All patients underwent contrast-enhanced multi-detector 
computed tomography to assist annular sizing and to assess aortic calcification prior to 
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TAVR. Percutaneous femoral artery access was the default approach, performed under 
either general anaesthesia or conscious sedation depending on patient suitability.  
CMR Protocol 
For each individual patient identical pre- and post-TAVR, and 6-month post-operative 
scans were performed at 1.5T (Intera or Ingenia, Phillips Healthcare, Best, Netherlands) 
as previously described (Figure 1) 25, 26. In brief, multi-slice, multi-phase cine imaging 
was performed using a standard steady-state free procession pulse sequence in the 
short axis (8/0mm, 30 phases, typical field of view (FOV) 340mm) to cover the entire left 
and right ventricle. For flow measurements, through-plane velocity encoded (VENC) 
phase contrast imaging was performed perpendicular to the aortic valve jet at the aortic 
sino-tubular junction, at the upper margin of the stent holding the TAVR prosthesis 
(VENC 200±500cm/s, retrospective gating, slice thickness 6mm, 40 phases, FOV 
340mm). This position for imaging has been previously described and validated 9. If 
significant turbulence or aliasing was seen in the velocity image, the acquisition was 
repeated a few millimetres further away from the valve, and/or with a higher-velocity 
window. In patients with AF, the use of multiple acquisitions and averaging of values, 
and the application of arrhythmia rejection (in which data points acquired from 
excessively long or short heart beats are rejected and reacquired) were employed 
where feasible. 
CMR Image Analysis 
Image analysis was performed in a blinded fashion, off-line using commercially 
available software (CVI42, Circle Cardiovascular Imaging, Calgary, Alberta, Canada) by 
two experienced observers. For LV mass and volumes, standard criteria were 
employed to delineate endocardial and epicardial borders at end-diastole and end-
systole and values obtained were indexed to body surface area as previously described 
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25
.  Papillary muscles were included within the LV cavity for the purpose of analysis and 
excluded from the LV mass. Aortic flow was quantified using cross-sectional phase 
contrast images with contouring of the aortic lumen to provide a peak forward flow 
velocity (m/s), forward flow volume (ml), backward flow volume (ml) for the calculation 
of trans-valvular pressure gradient (Bernoulli equation) and regurgitant fraction (RF,%). 
Images were excluded from analysis if artefacts from the TAVR were present on 
images. $RUWLF UHJXUJLWDWLRQ ZDV FODVVLILHG DV UHJXUJLWDQW IUDFWLRQ RI QRQHWULYLDO 
mild 6-15%, moderate 16-25%, moderate-severe 26-48%, and severe >48% in line with 
standard grading criteria 27. Intra-observer (12 random data sets 6 months apart) and 
inter-observer (12 data sets) agreement was assessed using the intra-class correlation 
coefficient. 
Sample Size and Statistical Analysis 
Based on published data 28 20 patients per group were required to detect a 10ml 
change in LVEDV or 10g difference in LV mass regression between the two treatments 
(90% power and an alpha error of 0.05). A sample size of 16 patients per treatment 
group was required to adequately power a two-sample comparison of mean aortic 
regurgitant fraction (again at 90% power and an alpha error of 0.05). Continuous 
variables are presented as mean±SD. Normality was determined by the Shapiro±Wilk 
test. Frequencies are reported as number (%). The Student t test and Wilcoxon signed 
rank test were used to compare continuous variables as appropriateDQGȤRU)LVKHU¶V
exact test for categorical comparisons. All statistical analyses were performed using the 
PASW software package (V.21.0 SPSS, IBM, Chicago, Illinois, USA) with a two-sided 
significance level of p<0.05 was considered statistically significant. 
 
RESULTS  
Patient population 
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A total of 51 patients (24 CoreValve and 27 Lotus valve) underwent both the pre-
operative (median 1 day pre-procedure, IQR 14 days) and immediate post-TAVR 
(median 4 days, IQR 4 days) CMR scans with 44 of these (19 CoreValve and 25 Lotus) 
finally completing 6-month post-TAVR scans. Reasons for non-completion of the CMR 
protocol were varied and are depicted in Figure 2. The final analysis population (n=44) 
was not different from the whole population (n=51) studied pre-TAVR (comparable in 
age (p=0.871), EuroSCORE II (p=0.724) and STS predicted operative mortality 
(p=0.736)). Baseline characteristics of the final study population are reported in Table 1.  
Measurement Variability 
Calculation of intra-class correlation coefficients indicated good intra- and inter-observer 
reproducibility of CMR measurements respectively: LVEDV (0.984, 0.989), LV mass 
(0.978, 0.985), LVEF (0.982, 0.970), peak aortic TAVR gradient (1.000, 0.963) and 
aortic regurgitant fraction post-TAVR (0.987, 0.986). 
Procedural data 
All of the Lotus valves were implanted via the femoral artery, as were the majority of 
CoreValves (67% femoral, 29% subclavian, 4% direct aortic). The size and frequency of 
device replacement is detailed in Table 2. Invasive resting trans-aortic pressure 
gradients were equivalent between the two groups, in keeping with baseline imaging. 
The implant procedure for a Lotus valve involved significantly longer fluoroscopy times, 
despite a significantly greater proportion of CoreValve TAVR receiving post-dilatation 
(0% vs. 28%, p=0.003). Equivalent volumes of contrast were used for each TAVR 
device (Table 2).   
VARC-defined device success 29 was achieved in 94% of the Lotus cohort and 63% of 
the CoreValve cohort (p= 0.004) at the immediate post-TAVR time point. The 
components of this measure were the absence of procedural mortality (94% vs. 96%, 
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p=0.177), a mean gradient across the TAVR prosthesis of <20mmHg (100% vs. 100%, 
p=0.999), correct positioning of a single TAVR prosthesis (100% vs. 96%, p=0.290), 
and no more than mild aortic regurgitation (100% vs. 63%, p=0.001) in the Lotus and 
CoreValve groups respectively. However, at the 6 month time-point, VARC defined 
success was equivalent between the two iterations; 91% Boston Lotus Vs. 89% for 
Medtronic CoreValve (p=0.827). The absolute rate of new pacemaker insertion was 
similar between the 2 groups (22% Lotus vs. 15% CoreValve, p=0.424). 
Haemodynamics 
The severity of pre-operative aortic valve stenosis was similar between the Lotus and 
CoreValve groups (Table 1). Systolic blood pressures (an important measure of LV 
afterload) remained comparable between the CoreValve and Lotus group both 
immediately (132±23 vs. 134±22mmHg, p=0.784) and at 6 months (141±25 vs. 
127±16mmHg respectively, p=0.161). Immediately post-TAVR, a significant reduction in 
peak aortic pressure gradient was observed in both Lotus (94.3±28.7 vs. 
25.4±11.6mmHg, p<0.001) and CoreValve (88.5±27.4 vs. 14.1±5.6mmHg, p<0.001) 
groups. However, the residual peak pressure gradient measured by CMR immediately 
following Lotus valve replacement was significantly higher than that following CoreValve 
(25.4±11.6 vs. 14.1±5.6mmHg, p=0.001). At 6 months post-TAVR, the peak pressure 
gradient of the CoreValve remained unchanged from the immediate post-TAVR time 
point (16.5±9.4 vs. 15.0±5.5mmHg respectively, p=0.457); however a significant 
reduction was observed in the Lotus group (25.8±12.1 vs. 19.7±10.5mmHg, p=0.022) 
(Figure 5A). As such, in comparison between CoreValve and Lotus patients, the 
residual peak pressure gradient at 6 months was equivalent (16.5±9.4 
vs.19.7±10.5mmHg, p=0.332) (Table 3). 
Immediately post-TAVR, the aortic regurgitant fraction was significantly greater in the 
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CoreValve group (11.7±8.4 vs. 4.3±3.4%, p=0.001). Similarly, the proportion of patients 
ZLWK PRGHUDWH$5 ZDV VLJQLILFDQWO\ KLJKHUZLWK &RUH9DOYH WKDQ/RWXV  
vs. 0/27 (0%), p<0.001) (Figure 3). Between the immediate and 6 month scans, the 
aortic regurgitant fraction in the Lotus group remained unchanged (4.0±3.5 vs. 
5.6±5.3%, p=0.267). However, a significant reduction was observed in the CoreValve 
patients (11.7±7.2 vs. 6.4±5.0%, p=0.002) (Figure 5B). As such, comparison between 
CoreValve and Lotus patients at 6 months showed that the residual total aortic 
regurgitant fraction was equivalent (6.4±5.0 vs. 5.6±5.3% respectively, p=0.623) (Table 
3). Importantly, of the 19 CoreValve patients who were imaged at 6 months, all of the 7 
patients with moderate AR immediately post-TAVR reduced to only mild AR, while 
three changed from mild to none/trivial AR There were no Lotus valve patients with 
moderate AR at any time point (Figure 4). 
LV reverse remodelling  
There were no significant differences in indexed LV end diastolic volume (LVEDV) 
(p=0.379), indexed LV mass (p=0.357), LV ejection fraction (LVEF) (p=0.306) or LV 
mass:volume ratio (p=0.329) between the groups at baseline. A direct comparison of LV 
morphology and function between the two groups, immediately and at 6 months post-
TAVR, is summarised in Table 3. Immediately post-TAVR, there was no change in 
indexed LVEDV or in LVEF in the Lotus group (p=0.550 and 0.498) or the CoreValve 
group (p=0.461 and 0.847) respectively. However, a significant reduction in the indexed 
LV mass occurred following CoreValve TAVR (75.4±15.0 vs. 65.8±13.6g/m2, p<0.001) 
that was not seen following Lotus (70.8±25.0 vs. 69.6±16.2g/m2, p=0.811). Compared 
to baseline, the LVEF and indexed LVEDV values at 6 months were unchanged, 
regardless of the valve type. However, at 6 months, a significant and comparable 
regression in the indexed LV mass was observed in both TAVR groups (Table 4, Figure 
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5C and 5D). 
 
DISCUSSION  
This is the first study to use CMR to directly and systematically compare two distinct 
TAVR designs for aortic valve regurgitation, haemodynamics and impact on LV reverse 
remodelling over time. The principal findings were as follows: 1. TAVR with the 
Medtronic CoreValve is associated with a significantly greater quantity of aortic 
regurgitation immediately post-replacement, with over a third of patients having at least 
moderate AR, compared to none with Lotus valve. 2. AR improves significantly with 
CoreValve over time, such that none of WKH SDWLHQWV ZLWK PRGHUDWH $5 immediately 
post-TAVR were left with more than mild AR at 6 months, and there was no longer a 
difference between valve types in mean aortic regurgitant fraction at 6 months. 3. The 
Lotus valve is associated with a significantly higher residual peak gradient than the 
CoreValve immediately post-TAVR. 4. Peak TAVR gradient fell significantly with the 
Lotus valve over time, with no difference between the valves at 6 months. 5. Despite 
the differences in aortic valve haemodynamics immediately post-TAVR, left ventricular 
reverse remodelling at 6 months was equivalent. This is consistent with published 
studies with longer follow-up that have demonstrated excellent outcomes with both 
TAVR prostheses 15, 30. 
 
Procedural Success 
In direct comparison, the VARC-defined primary composite outcome of device success 
was significantly higher in the Lotus group at the immediate post-TAVR time point, 
driven principally by the absence of moderate aortic regurgitation. The Lotus valve has 
been compared with the CoreValve previously using echocardiography 1; however 
these grading criteria suggested by VARC lack validation post-TAVR 31. In a recent 
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comparison of 2D and 3D echocardiography and CMR, applying VARC metrics post-
TAVR, the observer variability in determining AR was superior by CMR 12. This is the 
first study to our knowledge to assess device success using CMR, and using VARC 
criteria suggests superiority of the Lotus valve over CoreValve immediately post 
deployment. However, device success by the 6 month time point in our study was 
equivalent. 
  
Aortic Regurgitation following TAVR 
There is growing evidence suggesting a significant association of post-procedural AR 
with short- and long-term mortality 18, 32, 33. In a meta-analysis of 12,926 patients from 
45 studies (a majority using Edwards SAPIEN devices), moderate or more AR was 
associated with a 2.3-fold increase in 1 year mortality following TAVR 34. Our study 
used CMR to study the evolution of AR over time. No significant change was seen in 
the Lotus group from post-implant to 6 months, in line with REPRISE I 15 and REPRISE 
II 16. However, we did observe a significant reduction in AR at 6 months following 
CoreValve replacement. This is consistent with prior echocardiography studies, 
including the multicentre CoreValve US Pivotal Trial which indicated over 80% of 
patients exhibited an improvement of at least 1 grade of regurgitation at 1 year 35. A 
recent CMR study did suggest a small increase in AR at 6 months post-TAVR; but this 
study combined measurements of the CoreValve with those of another TAVR design 36. 
Our study is the first to use CMR to demonstrate a significant and clinically important 
improvement in AR over time; all patients with at least moderate AR immediately post-
TAVR having mild or less at 6 months. This may reflect continued outward expansion of 
the nitinol CoreValve frame 35, in contrast to the fixed mechanically locked Lotus frame. 
Interestingly, analysis of the large UK TAVR UHJLVWU\ VKRZHG PRGHUDWH $5 DIWer 
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CoreValve, in contrast to the SAPIEN valve, was not associated with increased long-
term mortality 37,  oXUILQGLQJWKDWPRGHUDWH$5SRVW-TAVR had resolved at 6 months 
in all cases may explain these findings. 
 
TAVR Pressure Gradients 
Immediately post-TAVR, we observed a lower residual aortic pressure gradient 
following CoreValve by an average of 10 mmHg when compared with the Boston Lotus. 
Previous studies have consistently shown that the CoreValve is associated with low 
residual gradients immediately post valve replacement 17, 19-21, probably due to the 
supra-annular position of the valve leaflets within the frame, isolating valve function 
from the surrounding anatomy. Our reported values with the Lotus valve are also 
comparable to those reported in previous echocardiographic studies 16. We do not have 
effective orifice area information as CMR does not permit accurate assessments in this 
context. Hence the degree of patient - prosthesis mismatch in our study remains 
unclear and would further clarify whether the pressure gradients represent poor 
individual sizing or a genuine reflection of TAVR design.  
 
LV Reverse Remodelling  
A significant finding of this study is the acute regression in LV mass index observed 
following the CoreValve but not the Lotus. Our group has previously reported acute 
reverse remodelling following TAVR with an average reduction in 8 g/m2 seen within the 
first week 38. In a sub-study of the PARTNER A trial, a notable portion of patients 
exhibited mass regression within the first 30 days 39. These findings may have clinical 
implications given that early LV mass regression following TAVR is associated with 
improved diastolic function 40, lower B-type Natriuretic Peptide levels and reduced 
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readmission to hospital for heart failure 39. The difference in immediate LV mass 
regression post TAVR may well be a consequence of the pressure gradients measured; 
with comparable reverse remodelling observed at 6 months when pressure gradients 
were similar. Given that the degree of LV mass regression and recovery of diastolic 
function after TAVR are positive prognostic indicators 41, 42 and residual hypertrophy 
detrimental 43, further work to validate these findings is merited. 
 
Limitations 
This was a small single-centre non-randomised comparison. Only patients clinically 
stable enough to participate in the CMR study were included.  Not all patients were able 
to complete the 6 month scan, predominantly due to pacemaker replacement or death, 
which may have introduced bias, although the final analysed population did not differ 
from the recruited population in terms of demographics and comorbidities. Our study did 
include patients in atrial fibrillation (18% in total) in whom there was potential 
quantification error.  Whilst the VARC-2 criteria include a measure of Patient-Prosthesis 
Mismatch, defined as absent when the TAVR effective regurgitant orifice area (EOA) is 
>0.85 cm2/m2 44, we assessed TAVR performance by the original VARC criteria 29, as 
our CMR protocol did not include imaging from which TAVR EOA could be ascertained. 
The VARC criteria are nonetheless widely accepted, forming the basis of a recent 
randomised clinical trial directly comparing two different TAVR systems 20. 
We used CMR to quantify the total AR seen following TAVR, which is a composite of 
para-valvular and trans-valvular regurgitation. Total aortic regurgitation following TAVR 
has been demonstrated as an important marker of mortality 45 and central trans-valvular 
regurgitation is usually minor and a physiological feature by virtue of prosthesis design 
31
. Furthermore, the VARC-2 criteria advocate a combined mHDVXUHPHQWRI³WRWDO´DRUWLF
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regurgitation (AR) reflecting the total regurgitant volume load imposed on the LV 44. 
Finally, this study utilised a different grading scale for aortic regurgitant fraction to that 
advocated by VARC-2, which is based primarily on data from native valve AR 
measurements. Our values are however entirely consistent with studies focusing on AR 
specifically after TAVR 9, 10. 
 
CONCLUSIONS 
Immediately post-TAVR, there was significantly less AR but a higher residual peak 
pressure gradient with the Lotus valve compared to CoreValve. However, at 6 months 
both devices had comparable valve haemodynamics and LV reverse remodelling. 
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FIGURE TITLES and LEGENDS 
 
Figure 1: CMR coronal views showing a Medtronic CoreValve (A) and Boston Lotus 
valve (B). 
Figure 2: Study profile. 
Figure 3: Aortic Regurgitation classification immediately post-TAVR   
Figure 4: Change in TAVR aortic regurgitation over time 
Figure 5: Comparison of change over time in valvular and ventricular parameters 
between the two TAVR designs (mean±SE). 
 
